SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head Results
What was SURMOUNT-5?
SURMOUNT-5 was a randomised, open-label Phase 3b clinical trial that did something the field had been waiting years for: it compared tirzepatide directly against semaglutide in the same study, rather than relying on cross-trial comparisons. Participants were adults with obesity (without type 2 diabetes), randomised to receive the maximum tolerated dose of one compound or the other over a 72-week treatment period, with percentage change in body weight as the primary endpoint.
Why it mattered: until SURMOUNT-5, claims that one incretin compound "beat" another were inferred from separate trials with different populations and designs — scientifically shaky. A head-to-head removes that ambiguity. That is exactly why it became one of the highest-interest metabolic-research events of the period.
The two compounds
Both belong to the incretin class, but they are built differently — which is the whole point of the comparison.
| Tirzepatide | Semaglutide | |
|---|---|---|
| Receptor targets | GIP + GLP-1 (dual agonist) | GLP-1 (single agonist) |
| Class position | Dual incretin agonist | First-generation GLP-1 agonist |
| Dosing studied | Weekly subcutaneous, escalating | Weekly subcutaneous, escalating |
| Research brand context | Studied as Mounjaro / Zepbound | Studied as Ozempic / Wegovy |
The mechanistic hypothesis going in: the added GIP component in tirzepatide might drive greater metabolic effect than GLP-1 agonism alone. For deeper background see our tirzepatide research summary and how GLP-1, dual and triple agonists relate.
The reported results
Headline outcome (as reported): tirzepatide produced a greater mean percentage body-weight reduction than semaglutide at the primary endpoint, meeting the trial's superiority objective. Widely reported figures placed tirzepatide at roughly ~20% mean reduction versus roughly ~14% for semaglutide over the 72 weeks — i.e. a clinically and statistically meaningful margin in favour of the dual agonist.
Tolerability: the adverse-event profile for both compounds was dominated by gastrointestinal events (nausea, diarrhoea, vomiting, constipation), predominantly during dose escalation — consistent with the incretin class as a whole and with no unexpected new safety signal reported between the two.
Interpretation: the result is the first head-to-head evidence that the dual GIP/GLP-1 mechanism can outperform GLP-1 agonism alone for weight reduction, under matched trial conditions. These are published research observations — not therapeutic claims, advice, or a recommendation.
What it means for the wider field
SURMOUNT-5 reframed the incretin conversation. If adding one extra receptor (GIP) to GLP-1 produces a measurable head-to-head advantage, the obvious research question becomes: what does adding a third receptor do? That is precisely the thread the triple agonist retatrutide (GIP/GLP-1/glucagon) is exploring, and why the dual GLP-1/glucagon agonist survodutide is also drawing attention. We set the full year in context in the Peptide Research Landscape 2026.
For the multi-way mechanistic comparison, see retatrutide vs tirzepatide vs semaglutide, plus retatrutide vs Wegovy and retatrutide vs Ozempic.
Availability
No compound referenced here is a medicine, and none is supplied for the uses discussed. Research reagents are supplied for in vitro use only. See our Research Use Policy.
References
- SURMOUNT-5: head-to-head trial of tirzepatide versus semaglutide for weight reduction in adults with obesity. N Engl J Med. 2025. PubMed: SURMOUNT-5
- SURMOUNT-5 trial record. ClinicalTrials.gov: SURMOUNT-5
Frequently Asked Questions
What is SURMOUNT-5?
A randomised, open-label Phase 3b clinical trial that directly compared tirzepatide with semaglutide for body-weight reduction in adults with obesity without type 2 diabetes — the first major head-to-head of the two.
Did tirzepatide or semaglutide perform better?
As reported, tirzepatide produced a greater mean percentage body-weight reduction than semaglutide at the primary endpoint (widely reported as roughly ~20% vs ~14% over 72 weeks). Published research observations — not therapeutic claims or advice.
Why did tirzepatide do better?
The leading hypothesis is its dual mechanism: tirzepatide agonises both GIP and GLP-1 receptors, whereas semaglutide targets GLP-1 alone. SURMOUNT-5 is the first head-to-head evidence that the added GIP component translates into a greater effect under matched conditions.
Are tirzepatide or semaglutide sold by Velox Peptides?
No. Neither is stocked. This is a research-reference summary only. The closest research compound we supply is retatrutide, a triple GIP/GLP-1/glucagon agonist.
